Lilly’ Phase-II Trial Results For LY2189265 Positive

Eli Lilly has announced positive phase II study results of LY2189265, an investigational glucagon-like peptide 1 (GLP-1) analog. It is to be administered subcutaneously once a week for the treatment of type 2 diabetes.

In the phase II study, LY2189265 was significantly superior to placebo in reducing key measures of glycemic control, including fasting serum glucose and hemoglobin A1C (HbA1C). In this study, LY2189265 showed an insulinotropic (stimulating the secretion of insulin) effect.

Pawel Fludzinski, Global Development Leader for the GLP-1Fc team, said: We are excited about these data and the hope they could provide to the millions of diabetes patients who are struggling to maintain tight control of their blood glucose.

Evaluating the results of this study is an important step forward towards potentially bringing this innovative treatment to patients, he added.